Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | TSPO | P30536 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.49 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KRAS | P01116 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27547403 | 0.92 | KDM4E (0.72) | KDM4ETSPOGLADNMT1AKR1B10 | |
| SCHEMBL15486750 | 0.91 | PTGDR2 (0.53) | KDM4ETSPOAKR1B1PTGDR2 | |
| SCHEMBL15486813 | 0.91 | PTGDR2 (0.51) | KDM4ETSPOGLADNMT1AKR1B10 | |
| SCHEMBL15485966 | 0.88 | PTGDR2 (0.52) | KDM4ETSPOGLADNMT1AKR1B10 | |
| SCHEMBL15486120 | 0.87 | TSPO (0.45) | KDM4ETSPOGLADNMT1AKR1B10 | |
| SCHEMBL21027003 | 0.85 | GLA (0.74) | KDM4ETSPOGLADNMT1AKR1B10 | |
| SCHEMBL15486330 | 0.84 | TSPO (0.43) | KDM4ETSPOGLADNMT1AKR1B10 | |
| SCHEMBL14689475 | 0.84 | TSPO (0.54) | TSPODNMT1MAPTKRASDNM1 | |
| SCHEMBL15489577 | 0.82 | KRAS (0.55) | TSPODNMT1MAPTKRASDNM1 | |
| SCHEMBL13403413 | 0.82 | FABP4 (0.59) | KDM4ETSPODNMT1MAPTDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318255-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2018-11-08 | — | — | US | claimed |
| EP-2925129-A1 | PRO-NEUROGENIC COMPOUNDS | Board of Regents of the University of Texas System (US) | 2015-10-07 | — | — | EP | claimed |
| WO-2014031125-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-27 | — | — | WO | claimed |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2013-02-14 | — | — | US | claimed |
| CN-112521328-A | Preparation method of 3-bromocarbazole | 中钢集团南京新材料研究院有限公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20190218203-A1 | Neuroprotective Compounds and Use Thereof | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2019-07-18 | — | — | US | disclosed |
| US-20190135809-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-09 | — | — | US | disclosed |
| US-20190135809-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-09 | — | — | US | disclosed |
| US-10183011-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-22 | — | — | US | disclosed |
| US-10183011-B2 | Anti-depression compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180318255-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2018-11-08 | — | — | US | disclosed |
| US-20180127367-A1 | Pro-Neurogenic Compounds | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2018-05-10 | — | — | US | disclosed |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2013-02-14 | — | — | US | disclosed |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2013-02-14 | — | — | US | disclosed |
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2012006419-A2 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006419-A2 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-01-12 | — | — | WO | disclosed |
| US-20020193369-A1 | Antifungal compounds and uses therefor | PROTEZ PHARMACEUTICALS INC. | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218203-A1 | Neuroprotective Compounds and Use Thereof | NLN, GAP43, BDNF | KDM4E 4319/4885TSPO 414/4885GLA 2056/4885 |
| US-20120022096-A1 | PRO-NEUROGENIC COMPOUNDS | BDNF, GAP43, DCX | KDM4E 4210/4885TSPO 2470/4885GLA 163/4885 |
| US-20180127367-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | KDM4E 4210/4885TSPO 2470/4885GLA 163/4885 |
| US-20020193369-A1 | Antifungal compounds and uses therefor | CYP51A1, ERG28, TPP1 | KDM4E 2603/4885TSPO 1327/4885GLA 1962/4885 |
| US-20180318255-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | KDM4E 4210/4885TSPO 2470/4885GLA 163/4885 |
| US-10183011-B2 | Anti-depression compounds | BDNF, DCX, GAP43 | KDM4E 3990/4885TSPO 2600/4885GLA 140/4885 |
| US-20190135809-A1 | Pro-Neurogenic Compounds | BDNF, NES, DCX | KDM4E 4356/4885TSPO 2302/4885GLA 179/4885 |
| US-20130040977-A1 | Pro-Neurogenic Compounds | BDNF, GAP43, DCX | KDM4E 4210/4885TSPO 2470/4885GLA 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.